D-19466, a new cyclobutane-platinum complex with antitumor activity.
D-19466, a new platinum complex, was characterized. It showed no nephrotoxic side-effects as determined by the measurement of blood urea. It was cytotoxic in vitro for tumor cells in concentrations comparable to or lower than cytotoxic concentrations of cisplatin. It had excellent anticancer activity in vivo against a number of murine experimental tumors, including a cisplatin-resistant P388 line. Clinical evaluation of this compound has therefore been initiated.
Voegeli
R
R
ASTA Pharma AG, Frankfurt, Federal Republic of Germany.
Schumacher
W
W
Engel
J
J
Respondek
J
J
Hilgard
P
P
D000818:Animals; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity; D003503:Cyclobutanes / Q000494:pharmacology*; D005260:Female; D007668:Kidney / Q000187:drug effects; D007939:Leukemia L1210 / Q000188:drug therapy*; D007941:Leukemia P388 / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D003503:Cyclobutanes; D009944:Organoplatinum Compounds; C066228:lobaplatin; D002945:Cisplatin